Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes
CARLSBAD, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, ES Cell International Pte Ltd. (ESI), a subsidiary of Lineage, and AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, today announced the broadening of their collaborative relationship with